In regards to ph2 starting after ph1. The company are going to persue a fast track approval which if granted could greatly speed up the trial timeline.
Not saying it will happen but accelerated pathways are definitely something they are going to seek and IMO have a very good chance of achieving this given the current unmet need for their targeted therapies
In regards to ph2 starting after ph1. The company are going to...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
